RevenanasBook a free audit

Funding

Blackstone Life Sciences and Boston Scientific in $455M heart pump co-funding deal

Biotech

Funding

Key Facts

Signal Type

Funding

Industry

Biotech

Companies

Boston Scientific, Blackstone Life Sciences, Medtronic

Date

What Happened

Blackstone Life Sciences has signed a $455 million collaboration with Boston Scientific to co-fund development of the Vitalyst Temporary Percutaneous Transvalvular Circulatory Support System. The device is designed to increase cardiac output and improve blood flow for patients with acute myocardial infarction cardiogenic shock.

This is the first co-funding arrangement between Boston Scientific and Blackstone, though Blackstone previously supported Medtronic's diabetes R&D programs in a similar partnership in 2020.

Who Is Affected

Boston Scientific's cardiovascular division will lead the program, with Blackstone Life Sciences as the investing partner. The target patient population is critically ill cardiogenic shock patients, where current mechanical circulatory support technologies have limitations in efficacy and safety.

Physicians treating acute heart attacks and related cardiac emergencies are directly affected, as the Vitalyst system aims to improve ease of use and patient outcomes. The program also signals a broader trend of life sciences investors co-funding device development with established medtech companies.

Market Impact

The $455 million capital injection into Boston Scientific's cardiovascular franchise will accelerate the Vitalyst program through development and regulatory milestones. Competitors in the temporary circulatory support space, including those with existing miniature heart pump technologies, will face a better-funded challenger.

  • Medtech R&D suppliers and clinical trial service providers may see new contracts from Boston Scientific's expanded program.
  • Regulatory affairs and reimbursement consultants should track the Vitalyst timeline for upcoming FDA interactions and clinical data readouts.
  • Hospital procurement teams and interventional cardiologists are early indicators for eventual adoption, making them important targets for awareness building.

What to Watch

Watch for Boston Scientific to announce clinical trial sites and enrollment milestones in coming quarters. The co-funding structure with Blackstone may also set a precedent for similar deals across Boston Scientific's pipeline.

Monitor competitive responses from Medtronic and other circulatory support developers, as well as regulatory progress. Any delay in Vitalyst development would affect the funding outlook and partner expectations.

Related coverage

Get biotech signals in your CRM

FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner